zidesamtinib

News

Nuvalent buy delivers new cancer approval for GSK

GSK has its first approval from the $10.6bn takeover of Nuvalent, ROS1+ NSCLC therapy Jideytro, which becomes the company's first lung cancer product.

News

GSK pursues $10.6bn takeover of cancer biotech Nuvalent

GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.

News

Nuvalent chases after Nuvation in ROS1 lung cancer

New trial data sets up a filing for Nuvalent's new-generation ROS1 inhibitor in NSCLC, although it has an uphill battle to catch rival Nuvation.

Nuvalent buy delivers new cancer approval for GSK

GSK pursues $10.6bn takeover of cancer biotech Nuvalent

Nuvalent chases after Nuvation in ROS1 lung cancer

US puts $125m into personalised RNA therapy production

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks